Table 3. The Association of Rapid Kidney Function Decline at Year 1 with Clinical Endpoints in SPS3 by Treatment Arm.

	Higher Target			Lower Target			P Interaction Treatment × Decline
	Rate per 1000 PY	Unadjusted HR (95% CI)	Adjusted* HR (95% CI)	Rate per 1000 PY	Unadjusted HR (95% CI)	Adjusted* HR (95% CI)
All Stroke
No Rapid Decline Year 1	24.1	ref	ref	21.5	ref	ref
Rapid Decline Year 1	51.6	2.13 (1.29, 3.52)	1.93 (1.15, 3.21)	21.4	0.99 (0.53, 1.86)	0.93 (0.50, 1.75)	0.06
Major Vascular Event
No Rapid Decline Year 1	30.1	ref	ref	27.5	ref	ref
Rapid Decline Year 1	58.6	1.95 (1.22, 3.13)	1.76 (1.09, 2.85)	25.4	0.92 (0.52, 1.63)	0.86 (0.48, 1.53)	0.05
Composite (death, MVE, MI or stroke)
No Rapid Decline Year 1	39.2	ref	ref	38.0	ref	ref
Rapid Decline Year 1	70.3	1.84 (1.20, 2.82)	1.62 (1.05, 2.51)	35.2	0.90 (0.55, 1.47)	0.83 (0.51, 1.35)	0.03

Hazard Ratios (HR) and 95% Confidence Intervals (CI) from Cox proportional hazard regression models

^*Adjusted for age, gender, ethnicity, smoking, diabetes, hypertension, use of ACE/ARB, baseline SBP, baseline eGFR

MVE (major vascular event) = Stroke, MI or vascular death

Rapid kidney function decline defined as eGFR decline ≥30% from baseline to year